{"ticker": {"uuid": "cbc81c38-7bd4-485e-9c8e-495b89bfe9aa", "symbol": "KYTX", "name": "Kyverna Therapeutics, Inc. Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNVkxXZmd0YnI0NXRrTC1mSE5JTGdVU1VaZk8yVHJ3WV9qRkl6RmF0Z0docWFOQkxsQ044RHl0bnBHZzNuQnFNUEc5QXl6WGE1aC1HdEswWlpPMEtEcmpWanl3S01uLV9WUEI5clFoS0E2dXZaQWhSRHExM1h1cklhY1pWSEFRSGJYWTJBeTVkU3FPZDctU29RV3FIUmF6cEZCeHJvS0lQQVVqOHpPSWEzTnlFeXNFbUdTbF94MFN6c28xZ1lCb2NxYmxvcjV6UUVN?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T04:52:28+00:00", "published_display": "14 Jul 2026 04:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kyverna Therapeutics Sinks 13%: Here\u2019s Why", "summary": "Kyverna Therapeutics (NASDAQ:KYTX) shares dropped almost 13% after JPMorgan cut its price target to $29, despite the company reporting better-than-expected Q1 2026 results and initiating a rolling BLA submission for its lead asset, miv-cel. The fresh analyst note is cited as the ", "url": "https://finance.yahoo.com/healthcare/articles/kyverna-therapeutics-sinks-13-why-195959588.html", "source_name": "Market source", "published_at": "2026-07-10T19:59:01", "published_display": "10 Jul 2026 19:59", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 11.1% - Time to Sell?", "summary": "Kyverna Therapeutics (NASDAQ:KYTX) stock dropped 11.1% in mid-day trading on Friday, with shares hitting $8.90. This decline occurred despite the clinical-stage biotech reporting a smaller-than-expected quarterly loss of ($0.66) per share, beating estimates. Analyst opinions are ", "url": "https://www.marketbeat.com/instant-alerts/kyverna-therapeutics-nasdaqkytx-shares-down-111-time-to-sell-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T16:40:18", "published_display": "10 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX Stock Price, Quote & Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE1EVm1fMDl6YWFIYW00S3hZQWczVm1oMWh0cTQ0V19TZEx3ZmN6MHZsdG5QZVVVanhRZUFMdEFpWG14SjJ1a1BxNk83eVFTNUstQ0JESUVPbFhBZXBBQk5R?oc=5", "source_name": "ChartMill", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Kyverna Therapeutics, Inc. \u2013 NASDAQ:KYTX", "summary": "This article provides the \"Price to sales forward\" metric for Kyverna Therapeutics, Inc. (NASDAQ: KYTX) as listed on TradingView. It indicates that the period value and changes for this financial metric are made available by humans. The content is primarily a data point for inves", "url": "https://www.tradingview.com/symbols/NASDAQ-KYTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T05:41:02", "published_display": "10 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Amends Term Loan, Extends Capital Access", "summary": "Kyverna Therapeutics recently amended its $150 million term loan facility with Oxford Finance, extending access to $15 million of Term A loans until year-end 2026. This amendment involves upfront and potential non-utilization fees and introduces contingent changes to Term B and T", "url": "https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-amends-term-loan-extends-capital-access", "source_name": "TipRanks", "published_at": "2026-07-10T05:41:01", "published_display": "10 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Kyverna Therapeutics, Inc. \u2013 NASDAQ:KYTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSHpNNkJfbXhQdC1PSmVtUllpR2VpbjFwMUxTeklVTkZpOGlaWDhiVEtBTm1EbFlPV0NvcUZzT3gwRmR6SXFDRmZNM09Ua18yQzBEME1GQmlPLTNhRzhROTl2VGxrZEwyd0UtcG5UOHc2N0ZuV29oRGNHVlNCOUE1VENXR1hYeWtfLUM1aDJYVzdvWV9QVzVXNlNKTDN5TVRUdG1KZXAxLVdyYzA?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T02:45:24+00:00", "published_display": "10 Jul 2026 02:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics (KYTX) Jefferies London Healthcare Conference 2025 Summary", "summary": "Kyverna Therapeutics (KYTX) presented at the Jefferies London Healthcare Conference 2025, highlighting their progress in CAR T therapies for autoimmune diseases. Their lead candidate, KYV-101, has shown strong efficacy and a favorable safety profile in over 100 patients across va", "url": "https://quartr.com/events/kyverna-therapeutics-inc-kytx-jefferies-london-healthcare-conference-2025_FLFdbMLY", "source_name": "Quartr", "published_at": "2026-07-09T17:40:18", "published_display": "09 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics\u2019 (KYTX) Insights into Stiff Person Syndrome and Beyond", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxONlJsY0NFM0lVRXdtWlpPRkt0cDlsVWRXa0pOYnZpRVhZa3NSc0t6WlJtSzh3LUkweXdla0kxUjhLeFpWNWZhazFCUWRnVko5c291c0Nxa2pQQVdUejVoNHQ3YThHQW5yTE1fdGZmVjNUVzVBdVBZMkVYc0FNZEtBUkM4ZzJUdG11T0xscFJwaHlyWlNXd0c4aUxBZkFNcVBLU3lV?oc=5", "source_name": "Market source", "published_at": "2026-07-09T13:22:54+00:00", "published_display": "09 Jul 2026 13:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics (KYTX) extends access to $150M term loan tranches", "summary": "Kyverna Therapeutics has amended its $150 million non-dilutive term loan facility with Oxford Finance, extending access to $15 million of Term A Loans until December 31, 2026, for an upfront fee of $187,500. This amendment also restructures the availability of subsequent tranches", "url": "https://www.stocktitan.net/sec-filings/KYTX/8-k-kyverna-therapeutics-inc-reports-material-event-acc34fa098cb.html", "source_name": "Stock Titan", "published_at": "2026-07-09T10:10:25", "published_display": "09 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics, Inc. $KYTX Shares Bought by AIGH Capital Management LLC", "summary": "AIGH Capital Management LLC increased its stake in Kyverna Therapeutics (NASDAQ:KYTX) by 33.3% in the first quarter, purchasing an additional 500,000 shares to bring their total holding to 2 million shares, valued at $17.26 million. This makes Kyverna Therapeutics the 10th larges", "url": "https://www.marketbeat.com/instant-alerts/filing-kyverna-therapeutics-inc-kytx-shares-bought-by-aigh-capital-management-llc-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T08:10:25", "published_display": "09 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS (KYTX)", "summary": "Kyverna Therapeutics is positioned to be a pioneer in the autoimmune CAR T space, with miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. The company has regulatory alignment for a rolling BLA submission for SPS, targeting FDA approval by ", "url": "https://seekingalpha.com/article/4919965-kyverna-therapeutics-stock-autoimmune-car-t-beachhead-bigger-than-sps", "source_name": "Seeking Alpha", "published_at": "2026-07-06T11:41:04", "published_display": "06 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX - Kyverna Therapeutics Inc Dividends", "summary": "This article provides comprehensive financial data for Kyverna Therapeutics Inc (KYTX), including its current stock price, market capitalization, income, sales, and various financial ratios. It highlights key performance metrics, insider and institutional ownership, and analyst r", "url": "https://finviz.com/stock?t=KYTX&p=m&ty=dv", "source_name": "Finviz", "published_at": "2026-07-01T10:39:58", "published_display": "01 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Index", "summary": "Kyverna Therapeutics, Inc. (NasdaqGS: KYTX) has been added to the Russell 2000 Index, as well as several other Russell benchmarks including the Russell 2500 Growth, Russell 2000 Growth, and Russell 3000 Index. This inclusion marks a significant milestone for the clinical-stage bi", "url": "https://www.marketscreener.com/news/kyverna-therapeutics-inc-nasdaqgs-kytx-added-to-russell-2000-index-ce7f5fdfdc8ff026", "source_name": "marketscreener.com", "published_at": "2026-06-30T02:09:12", "published_display": "30 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Microcap Growth Benchmark Index", "summary": "Kyverna Therapeutics, Inc. (NasdaqGS:KYTX) has been added to the Russell Microcap Growth Benchmark Index. This inclusion follows previous announcements of its addition to the Russell 2000 Growth and Russell 3000E Growth Benchmark Indices. Kyverna Therapeutics is a clinical-stage ", "url": "https://www.marketscreener.com/news/kyverna-therapeutics-inc-nasdaqgs-kytx-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df423", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:43:37", "published_display": "29 Jun 2026 12:43", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics, Inc. Actuals & Estimates (NASDAQ:KYTX)", "summary": "This article provides an overview of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) stock performance, financial data, and analyst estimates. It highlights the current stock price, market capitalization, historical highs and lows, and future price forecasts from analysts, along with d", "url": "https://www.tradingview.com/symbols/NASDAQ-KYTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:14", "published_display": "26 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Kyverna Therapeutics, Inc. (KYTX) stock, including price targets from analysts ranging from $25.00 to $33.00. It covers the stock's recent performance, volatility, market capitalization, and upcoming earnings report. The piece also includes fr", "url": "https://www.tradingview.com/symbols/NASDAQ-KYTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:46", "published_display": "25 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition", "summary": "Kyverna Therapeutics has appointed Ritesh Srivastava as its Chief Legal and Compliance Officer, bringing over two decades of legal and compliance experience in the healthcare sector. This strategic hire aims to strengthen Kyverna's leadership team as it prepares for a potential c", "url": "https://www.moomoo.com/hans/news/post/71828337/press-release-kyverna-therapeutics-appoints-ritesh-srivastava-as-chief-legal", "source_name": "Moomoo", "published_at": "2026-06-25T18:10:25", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition", "summary": "Kyverna Therapeutics has appointed Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026, to bolster its leadership as it transitions to a commercial-stage organization. Srivastava brings extensive experience in legal, corporate strategy, compliance, an", "url": "https://finance.yahoo.com/healthcare/articles/kyverna-therapeutics-appoints-ritesh-srivastava-120000161.html", "source_name": "Market source", "published_at": "2026-06-22T16:41:05", "published_display": "22 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Appoints Ritesh Srivastava as Chief", "summary": "Kyverna Therapeutics announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Srivastava brings extensive experience in legal, corporate strategy, compliance, and risk management, which will be crucial as Kyverna advances its ", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315237/0/en/kyverna-therapeutics-appoints-ritesh-srivastava-as-chief-legal-and-compliance-officer-adding-leadership-strength-to-support-commercial-stage-transition.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:40:20", "published_display": "22 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna adds legal chief as it prepares for commercialization", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOc2g3cVM3ZGo2b0pTYmVpRUEybUpUNzhYQng5S2pJYzUteWRuWEFvUWdtcGFFZXpKaWJYc2VpYWtpdlE3eTQ2ZnE0VGJtMk5rYzloaE5udnhfeWgyVXEzQjM1OF9UZnh5dzJSUGZMNm1MUkZwQTJ3d2ZLOTlYWWE2eFhlX1FzbWFhMjR5cEZQSzQ0eWU0N1ZDNkVyMjlSZ1N2ekhLV0dld3hma0xha29iZ0ZWMHE0eEY3eWw4ZjFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kyverna Therapeutics Names Greg Martini as Chief Financial Officer", "summary": "Kyverna Therapeutics has appointed Greg Martini as its new Chief Financial Officer. Martini brings over two decades of financial leadership experience in the biotechnology sector, including his previous role at Tempest Therapeutics. His appointment is expected to strengthen Kyver", "url": "https://www.moomoo.com/hans/news/post/70180255/press-release-kyverna-therapeutics-names-greg-martini-as-chief-financial", "source_name": "Moomoo", "published_at": "2026-06-20T22:10:37", "published_display": "20 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Inc (KYTX) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Kyverna Therapeutics Inc (KYTX), listing key institutional shareholders and their shareholdings. It highlights the changes in holdings for top firms like VV Manager LLC, Westlake Village BioPartners, and GordonMD Gl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kytx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:29", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Inc (KYTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Kyverna Therapeutics Inc (KYTX), detailing future EPS and revenue growth estimates. It highlights that analysts have a \"Buy\" rating for KYTX, with a target price indicating a significant upside. The report also includes past EPS perf", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kytx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:28", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Inc (KYTX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Kyverna Therapeutics Inc (KYTX) shareholder structure, listing major shareholders and their proportional holdings, as well as the types of shareholders. It also presents institutional shareholding data across several quarters, showing", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kytx/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T08:40:32", "published_display": "17 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Inc (KYTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Kyverna Therapeutics Inc (KYTX). It notes that relevant data for business segments, regional revenue, and profit contribution for FY2023, FY2022, and FY2021 have not yet been disclosed by the company. The current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kytx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T07:39:34", "published_display": "17 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics to Participate in Upcoming September Invest", "summary": "Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced its participation in three upcoming September investor conferences: the Morgan Stanley Global Healthcare Conference, the Wells Fargo Healthcare Conference, and the Cantor Gl", "url": "https://www.gurufocus.com/news/2507811/kyverna-therapeutics-to-participate-in-upcoming-september-investor-conferences?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-11T19:09:07", "published_display": "11 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX Stock Soars After Hours: What\u2019s Driving The Rally?", "summary": "Kyverna Therapeutics (KYTX) stock surged 24% after hours following the release of strong pivotal trial results for its one-time CAR-T therapy, miv-cel, in patients with stiff person syndrome. The trial showed significant improvements in mobility and disability reversal, with 81% ", "url": "https://stocktwits.com/news-articles/markets/equity/kytx-stock-soars-after-hours-whats-driving-the-rally/cZBB4WaRI6F", "source_name": "Stocktwits", "published_at": "2026-06-09T11:10:58", "published_display": "09 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/cb80c3bb-539d-32f8-bfcf-e7eb9c7c7cfe/kyverna-therapeutics-vs..html", "source_name": "Motley Fool", "published_at": "2026-06-08T18:54:25+00:00", "published_display": "08 Jun 2026 18:54", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX - Kyverna Therapeutics Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data, news, and analyst ratings for Kyverna Therapeutics Inc (KYTX). It details the company's stock performance, key financial metrics, recent executive appointments, and updates on its clinical trials and regulatory milestones, parti", "url": "https://finviz.com/stock?t=KYTX", "source_name": "Finviz", "published_at": "2026-06-05T04:09:34", "published_display": "05 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Blair Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating", "summary": "William Blair has reiterated its Buy rating for Kyverna Therapeutics (KYTX.US). This indicates continued confidence in the company's stock performance.", "url": "https://www.moomoo.com/news/post/71015915/william-blair-maintains-kyverna-therapeutics-kytxus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-04T16:10:58", "published_display": "04 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Kyverna stock rating on autoimmune data", "summary": "H.C. Wainwright maintained a Buy rating and $25.00 price target for Kyverna Therapeutics (NASDAQ: KYTX) after updated Phase 1 trial data for its miv-cel treatment in rheumatoid arthritis showed significant disease activity reduction and B-cell depletion without high-grade adverse", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-kyverna-stock-rating-on-autoimmune-data-93CH-4726417", "source_name": "Investing.com", "published_at": "2026-06-04T12:10:06", "published_display": "04 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX: Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and market potential", "summary": "Kyverna Therapeutics' (KYTX) Miv-cel CAR T therapy shows promising results in Stiff Person Syndrome (SPS) and generalized Myasthenia Gravis (gMG), demonstrating durable, drug-free remission with manageable side effects. The company is actively pursuing regulatory approval, with a", "url": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3470267:0-kytx-miv-cel-delivers-durable-drug-free-remission-in-sps-and-gmg-with-strong-safety-and-market-potential/", "source_name": "TradingView", "published_at": "2026-06-03T19:08:55", "published_display": "03 Jun 2026 19:08", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyverna-therapeutics-highlights-updated-miv-120000515.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna reports rheumatoid arthritis trial data at EULAR congress", "summary": "Kyverna Therapeutics Inc. (NASDAQ:KYTX) presented updated Phase 1 data from its COMPARE trial for miv-cel in treatment-refractory rheumatoid arthritis at the EULAR congress, showing positive results in disease activity reduction and B-cell depletion without significant safety con", "url": "https://www.investing.com/news/company-news/kyverna-reports-rheumatoid-arthritis-trial-data-at-eular-congress-93CH-4724150", "source_name": "Investing.com", "published_at": "2026-06-03T12:39:50", "published_display": "03 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Names Greg Martini CFO", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyverna-therapeutics-names-greg-martini-124807212.html", "source_name": "MT Newswires", "published_at": "2026-05-18T12:48:07+00:00", "published_display": "18 May 2026 12:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Names Greg Martini as Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyverna-therapeutics-names-greg-martini-120000046.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:00:00+00:00", "published_display": "18 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kyverna Therapeutics to Present at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyverna-therapeutics-present-upcoming-investor-120000567.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Watch Kyverna discuss autoimmune cell therapies at two live webcasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQLWJQa0U3R3VGM3JrNmVEYXlFSkJGNWVOS2NPRlE3UFZyZ0NONVhCUGlGSklqeExFaDJCY0NpbndETzlwQ2lpVldhYXU3bzQyN19YOWQyODhTVnJTSzE1cWR5Mk9tS0c2eEc4MHZPMWpFNUZxdE1oV1VGMGNBSnFHWkpGZW03bzJMNENVd1R5NG1ZNlE0UDl5MEdXOHAtRlRZVFA5UTYyNkFpN1U?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$KYTX stock is down 11% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZ0dtR1EyVDFvcEcyMjU2ZmtTSG1aNEdmejN2QVlpdWFieWVYUXVHT2FCMjRDSnVNLWtSa2hUOGs2bVhJN184ZG9TYkFfd29kUHF5eDNNOUlhZWxNU0dDOFNIWklJOEFGYVJBYlRIZVFEQ3VSRFY1OUloeWw3NDVZTDF2TnhZNWZCZkp0WFZCNjlWdzhqWFVBMl9rN0Z0N2RDMlFr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Kyverna pushes rare-disease CAR-T toward launch with cash into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWlJKN0x5OGtUeE50ODc5V0xZRGN3eHVwVEpvdTExV0IwaGtldWM4aG5RMXhlN2ZSSVdKU3hkY25SZThMTVctUHZRTGVsb1NDRDN4ektlN3NDVFJwVldyREJxWDQ0WWZKRWlBWTB0QkNvQk9RMTgtaGVnNkp2ekpkYlBCdFNmc0pNSTVWM3lwV05YS1lRZTBLTFQxQ1F3eFdTWWJxdUJUYjJuWmlocy1LdXd6Yi1meUNJcThV?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVnZ2eG1nOVFOMUFmWElrSTRiNzV0aUctcTJJN2lXUEpDLXpPMVZlQ2hjdlVCalVPWVZERnl2enV0aXpJc3hhZFA0UklFY3RhdkdtWTAxUHA1RjZ6TzRwT01HeHB4bXRQVDA4UmJSblBBdENseTBMcXpRV0lDMkNyTUM4M3M5N1pLcnNOYUJ6RzUxQ1F0cXFQaXVRd0Vrdk9XbUROSXhORm4?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNVkxXZmd0YnI0NXRrTC1mSE5JTGdVU1VaZk8yVHJ3WV9qRkl6RmF0Z0docWFOQkxsQ044RHl0bnBHZzNuQnFNUEc5QXl6WGE1aC1HdEswWlpPMEtEcmpWanl3S01uLV9WUEI5clFoS0E2dXZaQWhSRHExM1h1cklhY1pWSEFRSGJYWTJBeTVkU3FPZDctU29RV3FIUmF6cEZCeHJvS0lQQVVqOHpPSWEzTnlFeXNFbUdTbF94MFN6c28xZ1lCb2NxYmxvcjV6UUVN?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T04:52:28+00:00", "published_display": "14 Jul 2026 04:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Sinks 13%: Here\u2019s Why", "summary": "Kyverna Therapeutics (NASDAQ:KYTX) shares dropped almost 13% after JPMorgan cut its price target to $29, despite the company reporting better-than-expected Q1 2026 results and initiating a rolling BLA submission for its lead asset, miv-cel. The fresh analyst note is cited as the ", "url": "https://finance.yahoo.com/healthcare/articles/kyverna-therapeutics-sinks-13-why-195959588.html", "source_name": "Market source", "published_at": "2026-07-10T19:59:01", "published_display": "10 Jul 2026 19:59", "sentiment": "negative", "sentiment_pct": 19, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 11.1% - Time to Sell?", "summary": "Kyverna Therapeutics (NASDAQ:KYTX) stock dropped 11.1% in mid-day trading on Friday, with shares hitting $8.90. This decline occurred despite the clinical-stage biotech reporting a smaller-than-expected quarterly loss of ($0.66) per share, beating estimates. Analyst opinions are ", "url": "https://www.marketbeat.com/instant-alerts/kyverna-therapeutics-nasdaqkytx-shares-down-111-time-to-sell-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T16:40:18", "published_display": "10 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX Stock Price, Quote & Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE1EVm1fMDl6YWFIYW00S3hZQWczVm1oMWh0cTQ0V19TZEx3ZmN6MHZsdG5QZVVVanhRZUFMdEFpWG14SjJ1a1BxNk83eVFTNUstQ0JESUVPbFhBZXBBQk5R?oc=5", "source_name": "ChartMill", "published_at": "2026-07-10T07:00:00+00:00", "published_display": "10 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Kyverna Therapeutics, Inc. \u2013 NASDAQ:KYTX", "summary": "This article provides the \"Price to sales forward\" metric for Kyverna Therapeutics, Inc. (NASDAQ: KYTX) as listed on TradingView. It indicates that the period value and changes for this financial metric are made available by humans. The content is primarily a data point for inves", "url": "https://www.tradingview.com/symbols/NASDAQ-KYTX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T05:41:02", "published_display": "10 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Amends Term Loan, Extends Capital Access", "summary": "Kyverna Therapeutics recently amended its $150 million term loan facility with Oxford Finance, extending access to $15 million of Term A loans until year-end 2026. This amendment involves upfront and potential non-utilization fees and introduces contingent changes to Term B and T", "url": "https://www.tipranks.com/news/company-announcements/kyverna-therapeutics-amends-term-loan-extends-capital-access", "source_name": "TipRanks", "published_at": "2026-07-10T05:41:01", "published_display": "10 Jul 2026 05:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Kyverna Therapeutics, Inc. \u2013 NASDAQ:KYTX", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOSHpNNkJfbXhQdC1PSmVtUllpR2VpbjFwMUxTeklVTkZpOGlaWDhiVEtBTm1EbFlPV0NvcUZzT3gwRmR6SXFDRmZNM09Ua18yQzBEME1GQmlPLTNhRzhROTl2VGxrZEwyd0UtcG5UOHc2N0ZuV29oRGNHVlNCOUE1VENXR1hYeWtfLUM1aDJYVzdvWV9QVzVXNlNKTDN5TVRUdG1KZXAxLVdyYzA?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T02:45:24+00:00", "published_display": "10 Jul 2026 02:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics (KYTX) Jefferies London Healthcare Conference 2025 Summary", "summary": "Kyverna Therapeutics (KYTX) presented at the Jefferies London Healthcare Conference 2025, highlighting their progress in CAR T therapies for autoimmune diseases. Their lead candidate, KYV-101, has shown strong efficacy and a favorable safety profile in over 100 patients across va", "url": "https://quartr.com/events/kyverna-therapeutics-inc-kytx-jefferies-london-healthcare-conference-2025_FLFdbMLY", "source_name": "Quartr", "published_at": "2026-07-09T17:40:18", "published_display": "09 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics\u2019 (KYTX) Insights into Stiff Person Syndrome and Beyond", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxONlJsY0NFM0lVRXdtWlpPRkt0cDlsVWRXa0pOYnZpRVhZa3NSc0t6WlJtSzh3LUkweXdla0kxUjhLeFpWNWZhazFCUWRnVko5c291c0Nxa2pQQVdUejVoNHQ3YThHQW5yTE1fdGZmVjNUVzVBdVBZMkVYc0FNZEtBUkM4ZzJUdG11T0xscFJwaHlyWlNXd0c4aUxBZkFNcVBLU3lV?oc=5", "source_name": "Market source", "published_at": "2026-07-09T13:22:54+00:00", "published_display": "09 Jul 2026 13:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics (KYTX) extends access to $150M term loan tranches", "summary": "Kyverna Therapeutics has amended its $150 million non-dilutive term loan facility with Oxford Finance, extending access to $15 million of Term A Loans until December 31, 2026, for an upfront fee of $187,500. This amendment also restructures the availability of subsequent tranches", "url": "https://www.stocktitan.net/sec-filings/KYTX/8-k-kyverna-therapeutics-inc-reports-material-event-acc34fa098cb.html", "source_name": "Stock Titan", "published_at": "2026-07-09T10:10:25", "published_display": "09 Jul 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics, Inc. $KYTX Shares Bought by AIGH Capital Management LLC", "summary": "AIGH Capital Management LLC increased its stake in Kyverna Therapeutics (NASDAQ:KYTX) by 33.3% in the first quarter, purchasing an additional 500,000 shares to bring their total holding to 2 million shares, valued at $17.26 million. This makes Kyverna Therapeutics the 10th larges", "url": "https://www.marketbeat.com/instant-alerts/filing-kyverna-therapeutics-inc-kytx-shares-bought-by-aigh-capital-management-llc-2026-07-09/", "source_name": "MarketBeat", "published_at": "2026-07-09T08:10:25", "published_display": "09 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS (KYTX)", "summary": "Kyverna Therapeutics is positioned to be a pioneer in the autoimmune CAR T space, with miv-cel as a potential first-in-class therapy for severe B-cell-driven autoimmune diseases. The company has regulatory alignment for a rolling BLA submission for SPS, targeting FDA approval by ", "url": "https://seekingalpha.com/article/4919965-kyverna-therapeutics-stock-autoimmune-car-t-beachhead-bigger-than-sps", "source_name": "Seeking Alpha", "published_at": "2026-07-06T11:41:04", "published_display": "06 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 77, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX - Kyverna Therapeutics Inc Dividends", "summary": "This article provides comprehensive financial data for Kyverna Therapeutics Inc (KYTX), including its current stock price, market capitalization, income, sales, and various financial ratios. It highlights key performance metrics, insider and institutional ownership, and analyst r", "url": "https://finviz.com/stock?t=KYTX&p=m&ty=dv", "source_name": "Finviz", "published_at": "2026-07-01T10:39:58", "published_display": "01 Jul 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Index", "summary": "Kyverna Therapeutics, Inc. (NasdaqGS: KYTX) has been added to the Russell 2000 Index, as well as several other Russell benchmarks including the Russell 2500 Growth, Russell 2000 Growth, and Russell 3000 Index. This inclusion marks a significant milestone for the clinical-stage bi", "url": "https://www.marketscreener.com/news/kyverna-therapeutics-inc-nasdaqgs-kytx-added-to-russell-2000-index-ce7f5fdfdc8ff026", "source_name": "marketscreener.com", "published_at": "2026-06-30T02:09:12", "published_display": "30 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Microcap Growth Benchmark Index", "summary": "Kyverna Therapeutics, Inc. (NasdaqGS:KYTX) has been added to the Russell Microcap Growth Benchmark Index. This inclusion follows previous announcements of its addition to the Russell 2000 Growth and Russell 3000E Growth Benchmark Indices. Kyverna Therapeutics is a clinical-stage ", "url": "https://www.marketscreener.com/news/kyverna-therapeutics-inc-nasdaqgs-kytx-added-to-russell-microcap-growth-benchmark-index-ce7f5fded08df423", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T12:43:37", "published_display": "29 Jun 2026 12:43", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics, Inc. Actuals & Estimates (NASDAQ:KYTX)", "summary": "This article provides an overview of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) stock performance, financial data, and analyst estimates. It highlights the current stock price, market capitalization, historical highs and lows, and future price forecasts from analysts, along with d", "url": "https://www.tradingview.com/symbols/NASDAQ-KYTX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:14", "published_display": "26 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 61, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Kyverna Therapeutics, Inc. (KYTX) stock, including price targets from analysts ranging from $25.00 to $33.00. It covers the stock's recent performance, volatility, market capitalization, and upcoming earnings report. The piece also includes fr", "url": "https://www.tradingview.com/symbols/NASDAQ-KYTX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:46", "published_display": "25 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition", "summary": "Kyverna Therapeutics has appointed Ritesh Srivastava as its Chief Legal and Compliance Officer, bringing over two decades of legal and compliance experience in the healthcare sector. This strategic hire aims to strengthen Kyverna's leadership team as it prepares for a potential c", "url": "https://www.moomoo.com/hans/news/post/71828337/press-release-kyverna-therapeutics-appoints-ritesh-srivastava-as-chief-legal", "source_name": "Moomoo", "published_at": "2026-06-25T18:10:25", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition", "summary": "Kyverna Therapeutics has appointed Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026, to bolster its leadership as it transitions to a commercial-stage organization. Srivastava brings extensive experience in legal, corporate strategy, compliance, an", "url": "https://finance.yahoo.com/healthcare/articles/kyverna-therapeutics-appoints-ritesh-srivastava-120000161.html", "source_name": "Market source", "published_at": "2026-06-22T16:41:05", "published_display": "22 Jun 2026 16:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Appoints Ritesh Srivastava as Chief", "summary": "Kyverna Therapeutics announced the appointment of Ritesh Srivastava as Chief Legal and Compliance Officer, effective June 22, 2026. Srivastava brings extensive experience in legal, corporate strategy, compliance, and risk management, which will be crucial as Kyverna advances its ", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315237/0/en/kyverna-therapeutics-appoints-ritesh-srivastava-as-chief-legal-and-compliance-officer-adding-leadership-strength-to-support-commercial-stage-transition.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:40:20", "published_display": "22 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna adds legal chief as it prepares for commercialization", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOc2g3cVM3ZGo2b0pTYmVpRUEybUpUNzhYQng5S2pJYzUteWRuWEFvUWdtcGFFZXpKaWJYc2VpYWtpdlE3eTQ2ZnE0VGJtMk5rYzloaE5udnhfeWgyVXEzQjM1OF9UZnh5dzJSUGZMNm1MUkZwQTJ3d2ZLOTlYWWE2eFhlX1FzbWFhMjR5cEZQSzQ0eWU0N1ZDNkVyMjlSZ1N2ekhLV0dld3hma0xha29iZ0ZWMHE0eEY3eWw4ZjFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Kyverna Therapeutics Names Greg Martini as Chief Financial Officer", "summary": "Kyverna Therapeutics has appointed Greg Martini as its new Chief Financial Officer. Martini brings over two decades of financial leadership experience in the biotechnology sector, including his previous role at Tempest Therapeutics. His appointment is expected to strengthen Kyver", "url": "https://www.moomoo.com/hans/news/post/70180255/press-release-kyverna-therapeutics-names-greg-martini-as-chief-financial", "source_name": "Moomoo", "published_at": "2026-06-20T22:10:37", "published_display": "20 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Inc (KYTX) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Kyverna Therapeutics Inc (KYTX), listing key institutional shareholders and their shareholdings. It highlights the changes in holdings for top firms like VV Manager LLC, Westlake Village BioPartners, and GordonMD Gl", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kytx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:29", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Inc (KYTX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Kyverna Therapeutics Inc (KYTX), detailing future EPS and revenue growth estimates. It highlights that analysts have a \"Buy\" rating for KYTX, with a target price indicating a significant upside. The report also includes past EPS perf", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kytx/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:09:28", "published_display": "18 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Inc (KYTX) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of Kyverna Therapeutics Inc (KYTX) shareholder structure, listing major shareholders and their proportional holdings, as well as the types of shareholders. It also presents institutional shareholding data across several quarters, showing", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kytx/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T08:40:32", "published_display": "17 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Inc (KYTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Kyverna Therapeutics Inc (KYTX). It notes that relevant data for business segments, regional revenue, and profit contribution for FY2023, FY2022, and FY2021 have not yet been disclosed by the company. The current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-kytx/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T07:39:34", "published_display": "17 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics to Participate in Upcoming September Invest", "summary": "Kyverna Therapeutics, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced its participation in three upcoming September investor conferences: the Morgan Stanley Global Healthcare Conference, the Wells Fargo Healthcare Conference, and the Cantor Gl", "url": "https://www.gurufocus.com/news/2507811/kyverna-therapeutics-to-participate-in-upcoming-september-investor-conferences?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-11T19:09:07", "published_display": "11 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX Stock Soars After Hours: What\u2019s Driving The Rally?", "summary": "Kyverna Therapeutics (KYTX) stock surged 24% after hours following the release of strong pivotal trial results for its one-time CAR-T therapy, miv-cel, in patients with stiff person syndrome. The trial showed significant improvements in mobility and disability reversal, with 81% ", "url": "https://stocktwits.com/news-articles/markets/equity/kytx-stock-soars-after-hours-whats-driving-the-rally/cZBB4WaRI6F", "source_name": "Stocktwits", "published_at": "2026-06-09T11:10:58", "published_display": "09 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 93, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/cb80c3bb-539d-32f8-bfcf-e7eb9c7c7cfe/kyverna-therapeutics-vs..html", "source_name": "Motley Fool", "published_at": "2026-06-08T18:54:25+00:00", "published_display": "08 Jun 2026 18:54", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX - Kyverna Therapeutics Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data, news, and analyst ratings for Kyverna Therapeutics Inc (KYTX). It details the company's stock performance, key financial metrics, recent executive appointments, and updates on its clinical trials and regulatory milestones, parti", "url": "https://finviz.com/stock?t=KYTX", "source_name": "Finviz", "published_at": "2026-06-05T04:09:34", "published_display": "05 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "William Blair Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating", "summary": "William Blair has reiterated its Buy rating for Kyverna Therapeutics (KYTX.US). This indicates continued confidence in the company's stock performance.", "url": "https://www.moomoo.com/news/post/71015915/william-blair-maintains-kyverna-therapeutics-kytxus-with-buy-rating", "source_name": "Moomoo", "published_at": "2026-06-04T16:10:58", "published_display": "04 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Kyverna stock rating on autoimmune data", "summary": "H.C. Wainwright maintained a Buy rating and $25.00 price target for Kyverna Therapeutics (NASDAQ: KYTX) after updated Phase 1 trial data for its miv-cel treatment in rheumatoid arthritis showed significant disease activity reduction and B-cell depletion without high-grade adverse", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-kyverna-stock-rating-on-autoimmune-data-93CH-4726417", "source_name": "Investing.com", "published_at": "2026-06-04T12:10:06", "published_display": "04 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "KYTX: Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and market potential", "summary": "Kyverna Therapeutics' (KYTX) Miv-cel CAR T therapy shows promising results in Stiff Person Syndrome (SPS) and generalized Myasthenia Gravis (gMG), demonstrating durable, drug-free remission with manageable side effects. The company is actively pursuing regulatory approval, with a", "url": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3470267:0-kytx-miv-cel-delivers-durable-drug-free-remission-in-sps-and-gmg-with-strong-safety-and-market-potential/", "source_name": "TradingView", "published_at": "2026-06-03T19:08:55", "published_display": "03 Jun 2026 19:08", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyverna-therapeutics-highlights-updated-miv-120000515.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T12:00:00+00:00", "published_display": "03 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna reports rheumatoid arthritis trial data at EULAR congress", "summary": "Kyverna Therapeutics Inc. (NASDAQ:KYTX) presented updated Phase 1 data from its COMPARE trial for miv-cel in treatment-refractory rheumatoid arthritis at the EULAR congress, showing positive results in disease activity reduction and B-cell depletion without significant safety con", "url": "https://www.investing.com/news/company-news/kyverna-reports-rheumatoid-arthritis-trial-data-at-eular-congress-93CH-4724150", "source_name": "Investing.com", "published_at": "2026-06-03T12:39:50", "published_display": "03 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Names Greg Martini CFO", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyverna-therapeutics-names-greg-martini-124807212.html", "source_name": "MT Newswires", "published_at": "2026-05-18T12:48:07+00:00", "published_display": "18 May 2026 12:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Names Greg Martini as Chief Financial Officer", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyverna-therapeutics-names-greg-martini-120000046.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:00:00+00:00", "published_display": "18 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics to Present at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/kyverna-therapeutics-present-upcoming-investor-120000567.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T12:00:00+00:00", "published_display": "14 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Watch Kyverna discuss autoimmune cell therapies at two live webcasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQLWJQa0U3R3VGM3JrNmVEYXlFSkJGNWVOS2NPRlE3UFZyZ0NONVhCUGlGSklqeExFaDJCY0NpbndETzlwQ2lpVldhYXU3bzQyN19YOWQyODhTVnJTSzE1cWR5Mk9tS0c2eEc4MHZPMWpFNUZxdE1oV1VGMGNBSnFHWkpGZW03bzJMNENVd1R5NG1ZNlE0UDl5MEdXOHAtRlRZVFA5UTYyNkFpN1U?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$KYTX stock is down 11% today. Here's what we see in our data.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPZ0dtR1EyVDFvcEcyMjU2ZmtTSG1aNEdmejN2QVlpdWFieWVYUXVHT2FCMjRDSnVNLWtSa2hUOGs2bVhJN184ZG9TYkFfd29kUHF5eDNNOUlhZWxNU0dDOFNIWklJOEFGYVJBYlRIZVFEQ3VSRFY1OUloeWw3NDVZTDF2TnhZNWZCZkp0WFZCNjlWdzhqWFVBMl9rN0Z0N2RDMlFr?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna pushes rare-disease CAR-T toward launch with cash into 2028", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWlJKN0x5OGtUeE50ODc5V0xZRGN3eHVwVEpvdTExV0IwaGtldWM4aG5RMXhlN2ZSSVdKU3hkY25SZThMTVctUHZRTGVsb1NDRDN4ektlN3NDVFJwVldyREJxWDQ0WWZKRWlBWTB0QkNvQk9RMTgtaGVnNkp2ekpkYlBCdFNmc0pNSTVWM3lwV05YS1lRZTBLTFQxQ1F3eFdTWWJxdUJUYjJuWmlocy1LdXd6Yi1meUNJcThV?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOVnZ2eG1nOVFOMUFmWElrSTRiNzV0aUctcTJJN2lXUEpDLXpPMVZlQ2hjdlVCalVPWVZERnl2enV0aXpJc3hhZFA0UklFY3RhdkdtWTAxUHA1RjZ6TzRwT01HeHB4bXRQVDA4UmJSblBBdENseTBMcXpRV0lDMkNyTUM4M3M5N1pLcnNOYUJ6RzUxQ1F0cXFQaXVRd0Vrdk9XbUROSXhORm4?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 98, "total_relevant": 74, "sentiment_summary": {"positive": 26, "negative": 4, "neutral": 44, "score": 59, "total": 74, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 24.7, "count": 43}, {"event": "earnings", "label": "Earnings", "weight": 10.74, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 3.85, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.45, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 26, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 8.48, "latest_week": "2026-07-10", "one_week_move": -4.6, "four_week_move": 5.3, "twelve_week_move": -14.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.42089, "market_dynamics_buy_signal": false, "relative_strength": 0.954942, "fair_value_gap": 4.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 47.9237, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.6% over one week, +5.3% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 7}, {"label": "Stock Titan", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 67}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 43}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "67", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.6% over one week, +5.3% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today"}], "updated_at": "2026-07-16T06:04:01.437584+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}